Laboratory of clinical immunopharmacology

Laboratory staff
Head - Shirinsky Valery, MD, PhD, DSc, Professor, consultant rheumatologist, This email address is being protected from spambots. You need JavaScript enabled to view it. 
Leading researcher - Shirinsky Ivan, – MD, PhD, DSc, consultant rheumatologist,  This email address is being protected from spambots. You need JavaScript enabled to view it. 
Researcher - Kalinovskaya Natalia,MD, PhD
Junior research fellow - PolovnikovaOksana, MD, consultant rheumatologist,  This email address is being protected from spambots. You need JavaScript enabled to view it. 

Junior research fellow - Kazygasheva Elena, MD
PhD student - Shnaider Maria, MD

PhD student - Biryukova Anastasiya, MD

The laboratory was founded in 1987.

Research focus of the Laboratory of Clinical Immunopharmacology, Institute of Fundamental and Clinical Immunology

1. Statins and autoimmune disease

We evaluated pleiotropic effects of statins in rheumatoid arthritis and psoriasis (7,8) . These studies were completed several years ago.

2. Peroxisome proliferator-activated receptor alpha (PPARα) agonists in the treatment of RA and OA

We are interested in studying pleiotropic effects of PPARα agonists in RA and OA. Scientific evidence indicating that PPARα agonists may be beneficial for joint disease have been summarized in our review (9). In two pilot studies (10,11) we have shown that fenofibrate is associated with reduction of disease activity and improvement in lipid profile in patients with active RA receiving methotrexate and in patients with erosive OA. Currently we are performing a study of fenofibrate in patients with diabetes-associated knee OA. The rationale for this study is potential effects of fenofibrate on both OA and diabetes-related pathology.

3. Diabetes-associated osteoarthritis

We are interested in evaluating clinical features and biomarkers of diabetes-associated OA. We performed a cross-sectional study on a small local cohort of diabet-associated OA patients in whom the diagnosis of diabetes had preceded the diagnosis of OA by at least 1 year. The results have been published in local journals (2,3,4). We have also evaluated longitudinal effects of diabetes on OA-related knee pain and function in patients from Osteoarthritis Initiative Cohort (12).

4. Epigenetic modulators in the treatment of OA and RA (6)

We have recently been studying the effects of various modulators of DNA methylation (S-adenosyl L-methyonine, genistein) on phenotype of RA synovial fibroblasts in vitro. The studies are ongoing and the results have not been published.

5. In the future we would like to continue research on comorbidity and multimorbidity in OA. We also would like to initiate studies in etnopharmacology and network pharmacology of OA (1).

Since 2003 our laboratory has been participating in more than 25 phase II-III clinical trials in rheumatology (rheumatoid arthritis, psoriatic arthritis) and clinical immunology (asthma).

Selected recent publications 

1. Ширинский И.В., Ширинский В.С. Узловая терапия – новая возможность лечения коморбидных заболеваний. Сибирский медицинский журнал. - 2014. - Т. 29, № 4, С.13-22

2. Ширинский И.В., Калиновская Н.Ю., Сазонова О.В., ШиринскийВ.С. Биомаркеры атеросклероза у больных диабет – ассоциированным остеоартритом» Вестник уральской медицинской академической науки, 2014, № 5 (51), стр. 23–28

3. Ширинский И.В., Калиновская Н.Ю., Ширинский В.С. Клинико-иммунологическая характеристика диабет-ассоциированного остеоартрита. Медицинская иммунология , 2015, Т17, 1, стр. 87-92

4. Ширинский И.В., О. В. Сазонова, Н. Ю. Калиновская, В. С. Ширинский. Коморбидность, метилирование ДНК и аутоиммунитет при диабет-ассоциированном остеоартрите: поисковое исследование. Медицинская иммунология, 2015, Том 17, № 4, C.327-334

5. Ширинский В.С., О.В. Величкина, Ширинский И.В. В.А. Козлов Эффективность акупунктуры у больных с диабет-ассоциированным остеоартритом, Вестник НГУ, 2015, Т13, №3, С. 25-30

6. Ширинский И.В., Сазонова О.В., Калиновская Н.Ю., Ширинский В.С. Клиническая эффективность и безопасность применения адеметионина у больных диабет-ассоциированным остеоартритом - пилотное исследование. Медицинская иммунология, 2015, Т. 17, № 6, C.553-560

7. Shirinsky IV, Zheltova OI, Solovyova NY, Kozlov VA, Shirinsky VS. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand. J. Rheumatol. 2009;38(1):23-7.

8. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: A pilot study. J. Am. Acad. Dermatol. 2007;57(3):529-31.

9. Shirinsky IV, Shirinsky VS. Targeting Nuclear Hormone Receptors: PPARalpha Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis. Int J Rheumatol 2011;2011:937843.

10. Shirinsky I, Polovnikova O, Kalinovskaya N, Shirinsky V. The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study. Rheumatol. Int. 2013;33(12):3045-8.

11. Shirinsky IV, Shirinsky VS. Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study. Rheumatol. Int. 2014;34(5):613-6.

12. Shirinsky I, Shirinsky V. OP0026 Diabetes Effects on Pain and Physical Function in Incidence and Progression Subcohorts of the Osteoarthritis Initiative: A 5-Year Longitudinal Data Analysis. Ann. Rheum. Dis. 2013;72(Suppl 3):A56-A57.

Contacts:
Tel/fax: +73832282547